Trial · NCT05166343
POHCA Resuscitation: Evaluation of IM Epinephrine
NCT05166343, Phase 2, Phase 3, Recruiting, London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. POHCA Resuscitation: Evaluation of IM Epinephrine. Trials, record NCT05166343. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05166343
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- POHCA Resuscitation: Evaluation of IM Epinephrine
- NCT number
- NCT05166343
- Status
- Recruiting
- Phases
- Phase 2, Phase 3
- Enrollment
- 284 participants, estimated
- Lead sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
- Conditions
- Pediatric Out-of-Hospital Cardiac Arrest
- Interventions
- Epinephrine Injection
- First posted
- 2021-12-21
- Last updated
- 2025-03-11
Source ClinicalTrials.gov
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Time to initial return of spontaneous circulation (ROSC) | At time of event | The primary outcome will be the time to initial ROSC. The investigator will compare time to initial ROSC between the standard of care and intervention periods. |
| Secondary | Return of spontaneous circulation | At time of event | Whether return of spontaneous circulation is achieved or not |
| Secondary | Time to sustained ROSC | At time of event | Time to sustained ROSC will be calculated from the time that paramedics arrive on scene to the time that sustained ROSC, defined as chest compressions not required for 20 minutes with persistent signs of circulation, is achieved. |
| Secondary | Survival | From time of event to ED admission | Survival to emergency department transfer to pediatric critical care unit (PCCU), if applicable: admitted to PCCU from external ED |
| Secondary | Survival - comparison between both arms | From time of event to hospital admission | Survival to hospital admission will be compared between standard of care and intervention periods |
| Secondary | PCCU/Hospital length of stay | From time of hospital/PCCU admission to discharge, up to 1 year | PCCU and hospital length of stay will be calculated from time of admission to the PCCU/hospital and time to discharge from PCCU/hospital, if applicable, between standard of care and intervention periods |
| Secondary | Survival to hospital discharge | Dependent on course of hospital stay, up to 1 year | Survival to hospital discharge will be compared between standard of care and intervention periods |
| Secondary | Post POHCA survival | Dependent on survival at 6 and 12 month period post POHCA event | Survival at 6 months and 12 months post-POHCA will be compared between standard of care and intervention periods |
| Secondary | Neurological status | From time of discharge and 6 and 12 months post POHCA event | The investigator will compare PCPC scores at discharge, 6- and 12-months post-POHCA between the standard of care and intervention periods |
| Secondary | Life Impact and Pediatric Quality of Life assessments | 6 and 12 months post POHCA event | Life Impact assessment between 6 and 12 months: the investigator will use the Pediatric Quality of Life (PEDSQoL, Pediatrics Quality of Life) assessment tool at 6- and 12-months post-POHCA in all survivors and compare between standard of care and intervention periods. The score ranges from 0-100, with higher scores indicating better outcome. |
1 to 10 of 11Source ClinicalTrials.gov
See all 11 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 42260675 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05166343
GET https://conductscience.org/api/trials/v1/NCT05166343/registered